A Phase 2 interventional study of WD-1603 Carbidopa-Levodopa Extended-Release Tablets and Placebo in Parkinson Disease, sponsored by Shanghai WD Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Shanghai WD Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.
Among the 279 studies in Parkinson Disease with a site in China, this one is the 110th largest by enrollment of the 211 interventional ones that give a count, is one of 21 that started in 2021, is one of 13 in phase 2, and was the 108th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Anhui Medical University · Sites in China
Ages 30–75
Hoffmann-La Roche · Sites in China, United States, Ireland and 2 more countries
Ages 40–85
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 18–80
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 30–75
Ruijin Hospital · Sites in China
Ages 50–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 28 · Phase 3 23 · Phase 4 11
First in 2003; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 47 across the 211 interventional studies, 215 across the 68 observational. Of the 97 that completed or were terminated, 19 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 279 have an industry lead sponsor. The 10 most frequent:
Shanghai WD Pharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Shanghai WD Pharmaceutical Co., Ltd. has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
41 of the studies in Parkinson Disease with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725562Phase 3Zhejiang Vimgreen Pharmaceuticals, Ltd.VG081821AC Tablets for Early to Mid-stage Parkinson's Disease | 2027-10-01 |
| NCT07028632iRegene Therapeutics Co., Ltd.The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | 2026-12 |
| NCT07604116Synusight Biotech (Shanghai) Co., Ltd.A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | 2026-12 |
| NCT06642454Anhui Medical UniversityA Randomized Double-Blind Active-Controlled Crossover Trial of Respiratory-Gated Versus Non-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 279 studies in Parkinson Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson's disease.
Eligible subjects of the study will be randomly assigned into four groups at a ratio of 1:1:1:1: three treatment groups and one placebo group. The subjects will take trial drugs orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25/100mg WD-1603
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
25/150mg WD-1603
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
2x25/100mg WD-1603
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
placebo are tablets-matching with the same active groups.
Drug: Placebo
Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
Also known as: WD-1603
placebo tablets-matching the active groups.
Also known as: Placebo of WD-1603
Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores = greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 27 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.
Time frame: 27 days- from the baseline to the 27th day
Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day.
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores on both parts indicate greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 14 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.
Time frame: 14 days-from the baseline to the 14th day
Changes in MDS-UPDRS-II Scores From the Baseline to the 14th and 27th Days.
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Motor Experiences of Daily Living) is a 13-item scale used to assess motor experiences of daily living in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part II total score ranges from 0 to 52. Higher scores indicate more severe impairment in motor experiences of daily living (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -52 to +52. A negative change indicates improvement, while a positive change indicates worsening.
Time frame: 14 days and 27 days-from the baseline to the 14th and 27th day
Changes in the MDS-UPDRS-III Scores From the Baseline to the 14th and 27th Days.
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) contains 33 scores based on 18 items and is used to assess motor impairment in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part III total score ranges from 0 to 132. Higher scores indicate more severe motor impairment (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -132 to +132. A negative change indicates improvement in motor impairment, while a positive change indicates worsening.
Time frame: Baseline to Day 14 and Baseline to Day 27.
Cmax (Maximum Plasma Concentration) of the Pharmacokinetics of WD-1603
Cmax (Maximum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.
Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose.
Cmin (Minimum Plasma Concentration) of the Pharmacokinetics of WD-1603.
Cmin (Minimum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.
Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
AUC0-τ and AUC0-∞ of Levodopa and Carbidopa Following WD-1603 Administration on Day 28.
Plasma concentrations of levodopa and carbidopa were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The area under the plasma concentration-time curve from time 0 to τ (AUC0-τ) was calculated using the linear trapezoidal method, where τ is the dosing interval of 5 hours. The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) was calculated as AUC0-t + Clast/λz, where AUC0-t is the AUC from time 0 to the last measurable concentration (Clast), and λz is the terminal elimination rate constant. AUC values are presented in ng\*h/mL for both levodopa and carbidopa. Higher AUC values indicate greater systemic exposure.
Time frame: 1 day- on the 28th day
Levodopa Plasma Concentration Fluctuation Index of WD-1603.
Plasma levodopa concentrations were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The fluctuation index was calculated as (Cmax - Cmin) / Cavg, where Cmax is the maximum plasma concentration, Cmin is the minimum plasma concentration, and Cavg is the average plasma concentration calculated as AUC0-τ / τ, with τ = 5 hours. A higher fluctuation index indicates greater fluctuation in plasma levodopa concentration.
Time frame: Day 28: 0, 0.5,1, 2, 3, 4,5, 6, 9 hours post-dose
Adverse Events (AEs) in Patients With Parkinson's Disease Treated With WD-1603.
Adverse events (AEs) refer to any untoward medical occurrence in participants, which may present as symptoms and signs, diseases, or abnormal laboratory findings, and may not necessarily have a causal relationship with the study drug. An event was recorded as an AE if at least one of the following criteria was met: (1) accompanying symptoms and signs; (2) examination results requiring treatment measures (such as surgical intervention); or (3) examination results leading to changes in the dosing schedule of the study drug (such as dose change, dosing delay, or discontinuation). The number and percentage of participants with AEs are reported.
Time frame: 28 days-from baseline to the 28th day.
Beck Depression Inventory-II (BDI-II) Scale of WD-1603 in Patients With Parkinson's Disease.
BDI-II scores are collected for safety assessment. BDI-II is a 21-item self-administered survey which is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.
Time frame: 28 days-from baseline to the 28th day.
A total of 54 patients with early-stage Parkinson's disease were screened at 5 clinical research centers across China. The first participant was enrolled on November 25, 2021, and the last participant completed the study on December 28, 2022.
| Milestone | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 |
| Completed | 9 | 9 | 9 | 8 |
| Not completed | 1 | 1 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 2 |
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores = greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 27 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.
| units on a scale | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day. | -7.4 ± 2.57 | -9.2 ± 2.54 | -14.3 ± 2.54 | -0.7 ± 2.57 |
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses Parkinson's disease impairment. Part II (Motor Experiences of Daily Living) has 13 items; Part III (Motor Examination) has 33 scores from 18 items. Each item is rated 0-4 (0=normal, 1=slight, 2=mild, 3=moderate, 4=severe). Part II total 0-52; Part III total 0-132. Higher scores on both parts indicate greater severity. Combined score = sum of Part II and III totals, range 0-184; higher = worse motor impairment. Change from baseline = Day 14 score minus baseline. Change scores range -184 to +184; negative = improvement, positive = worsening.
| units on a scale | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 14th Day. | -5.9 ± 2.30 | -7.9 ± 2.28 | -11.6 ± 2.28 | 0.1 ± 2.31 |
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Motor Experiences of Daily Living) is a 13-item scale used to assess motor experiences of daily living in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part II total score ranges from 0 to 52. Higher scores indicate more severe impairment in motor experiences of daily living (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -52 to +52. A negative change indicates improvement, while a positive change indicates worsening.
| units on a scale | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Change from baseline to Day 14 | -2.1 ± 0.77 | -2.6 ± 0.77 | -2.9 ± 0.77 | -0.5 ± 0.78 |
| Change from baseline to Day 27 | -2.2 ± 0.90 | -3.3 ± 0.91 | -3.5 ± 0.91 | -1.2 ± 0.92 |
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) contains 33 scores based on 18 items and is used to assess motor impairment in Parkinson's disease. Each item is rated on a 0-4 scale (0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = severe). The Part III total score ranges from 0 to 132. Higher scores indicate more severe motor impairment (worse outcome). Change from baseline is calculated separately for Day 14 and Day 27 as the score at each time point minus the baseline score. Change scores range from -132 to +132. A negative change indicates improvement in motor impairment, while a positive change indicates worsening.
| units on a scale | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Change from baseline to Day 14 | -3.8 ± 1.84 | -5.3 ± 1.81 | -8.6 ± 1.81 | 0.5 ± 1.87 |
| Change from baseline to Day 27 | -5.4 ± 2.05 | -5.9 ± 2.02 | -10.8 ± 2.02 | 0.8 ± 2.09 |
Cmax (Maximum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.
| ng/mL | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group |
|---|---|---|---|
| Levodopa | 576.4 ± 204.45 | 751.9 ± 293.76 | 1421.1 ± 529.93 |
| Carbidopa | 70.33 ± 26.775 | 62.83 ± 25.96 | 188.84 ± 102.11 |
Cmin (Minimum Plasma Concentration) of Levodopa and Carbidopa Following WD-1603 Administration.
| ng/mL | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group |
|---|---|---|---|
| Levodopa | 157.62 ± 93.71 | 212.20 ± 95.67 | 413.08 ± 216.41 |
| Carbidopa | 24.66 ± 13.54 | 24.70 ± 14.55 | 81.94 ± 40.08 |
Plasma concentrations of levodopa and carbidopa were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The area under the plasma concentration-time curve from time 0 to τ (AUC0-τ) was calculated using the linear trapezoidal method, where τ is the dosing interval of 5 hours. The area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) was calculated as AUC0-t + Clast/λz, where AUC0-t is the AUC from time 0 to the last measurable concentration (Clast), and λz is the terminal elimination rate constant. AUC values are presented in ng\*h/mL for both levodopa and carbidopa. Higher AUC values indicate greater systemic exposure.
| ng*h/mL | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group |
|---|---|---|---|
| Levodopa AUC0-τ | 1681.30 ± 552.67 | 2466.67 ± 1051.90 | 4711.66 ± 1376.00 |
| Carbidopa AUC0-τ | 231.00 ± 76.09 | 228.13 ± 96.86 | 718.03 ± 409.25 |
| Levodopa AUC0-∞ | 2935.53 ± 1079.51 | 4561.93 ± 1105.60 | 7204.29 ± 2420.39 |
| Carbidopa AUC0-∞ | 524.17 ± 470.34 | 457.63 ± 195.54 | 1162.49 ± 503.33 |
Plasma levodopa concentrations were measured on Day 28 at pre-dose (0 hour) and 0.5, 1, 2, 3, 4, 5, 6, and 9 hours after the second dose. The fluctuation index was calculated as (Cmax - Cmin) / Cavg, where Cmax is the maximum plasma concentration, Cmin is the minimum plasma concentration, and Cavg is the average plasma concentration calculated as AUC0-τ / τ, with τ = 5 hours. A higher fluctuation index indicates greater fluctuation in plasma levodopa concentration.
| index | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group |
|---|---|---|---|
| Levodopa Plasma Concentration Fluctuation Index of WD-1603. | 1.3 ± 0.42 | 1.16 ± 0.53 | 1.09 ± 0.43 |
Adverse events (AEs) refer to any untoward medical occurrence in participants, which may present as symptoms and signs, diseases, or abnormal laboratory findings, and may not necessarily have a causal relationship with the study drug. An event was recorded as an AE if at least one of the following criteria was met: (1) accompanying symptoms and signs; (2) examination results requiring treatment measures (such as surgical intervention); or (3) examination results leading to changes in the dosing schedule of the study drug (such as dose change, dosing delay, or discontinuation). The number and percentage of participants with AEs are reported.
| Participants | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Adverse Events (AEs) in Patients With Parkinson's Disease Treated With WD-1603. | 5 | 2 | 7 | 3 |
BDI-II scores are collected for safety assessment. BDI-II is a 21-item self-administered survey which is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.
| points | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Beck Depression Inventory-II (BDI-II) Scale of WD-1603 in Patients With Parkinson's Disease. | -1.3 ± 1.87 | -0.7 ± 1.41 | -2.1 ± 2.32 | -1.2 ± 1.48 |
Collected over From first dose up to 7 days after the last dose (up to a total of 37 days).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 25/100mg Treatment Group | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| 25/150mg Treatment Group | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| 2x25/100mg Treatment Group | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Placebo Group | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Event | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group |
|---|---|---|---|---|
| Orthostatic hypotensionVascular disorders | 1/10 | 1/10 | 3/10 | 0/9 |
| DizzinessNervous system disorders | 1/10 | 1/10 | 2/10 | 0/9 |
| Supraventricular extrasystolesCardiac disorders | 0/10 | 0/10 | 0/10 | 1/9 |
| Right bundle branch blockCardiac disorders | 0/10 | 0/10 | 0/10 | 1/9 |
| Clavicle FractureInjury, poisoning and procedural complications | 0/10 | 0/10 | 0/10 | 1/9 |
| NeuralgiaNervous system disorders | 1/10 | 0/10 | 0/10 | 0/9 |
| HeadacheNervous system disorders | 1/10 | 0/10 | 0/10 | 0/9 |
| ConstipationGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 0/9 |
| NauseaGastrointestinal disorders | 0/10 | 0/10 | 1/10 | 0/9 |
| VomitingGastrointestinal disorders | 0/10 | 1/10 | 0/10 | 0/9 |
All participants who were enrolled and randomized to each study group.
| Age, Continuous(years) | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 56.6 ± 9.47 | 60.4 ± 10.63 | 61.7 ± 8.64 | 60.3 ± 12.54 | 59.8 ± 10.20 |
| Sex: Female, Male(Participants) | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Female | 4 | 3 | 7 | 1 | 15 |
| Male | 6 | 7 | 3 | 9 | 25 |
| Ethnicity (NIH/OMB)(Participants) | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 10 | 10 | 10 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Duration of Parkinson's Disease(months) | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 4.5 ± 5.71 | 11.2 ± 18.31 | 13.9 ± 22.82 | 9.4 ± 13.37 | 9.8 ± 16.07 |
| Modified Hoehn & Yahr Score(Participants) | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group | Total |
|---|---|---|---|---|---|
| 1 | 3 | 0 | 1 | 1 | 5 |
| 1.5 | 0 | 1 | 1 | 2 | 4 |
| 2 | 4 | 7 | 1 | 5 | 17 |
| 2.5 | 3 | 2 | 7 | 1 | 13 |
| Presence of orthostatic hypotension(Participants) | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Yes | 1 | 0 | 2 | 0 | 3 |
| No | 9 | 10 | 8 | 10 | 37 |
| Beck Depression Inventory Scale Score(units on a scale) | 25/100mg Treatment Group | 25/150mg Treatment Group | 2x25/100mg Treatment Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 4.9 ± 3.51 | 8.7 ± 11.33 | 6.1 ± 3.07 | 5.0 ± 4.77 | 6.2 ± 6.54 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Dec 2022, 13 months.
Results were first posted in Oct 2026, 3 years 9 months after primary completion.
Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 13 months is below that.
Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: WD-1603
Shanghai WD Pharmaceutical Co., Ltd.